gland pharma glp-1 manufacturing capacity india reported a strong December quarter with 22.5% revenue growth and 27% YoY profit growth, driven by healthy performance across the US, India, and Europe. The stock reacted positively, gaining over The GLP-1 Inflection: Why March

10.1161/STROKEAHA.111.617589 Stroke 93 ShaR.XuY.YuanC.ShengX.WuZ.PengJ.et al (2021)

The company describes retatrutide as an investigational once-weekly triple-hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors with a single molecule.[4] This development history is important because retatrutide was designed as a next-generation incretin therapy rather than as a simple modification of an existing GLP-1 agent

A realistic earliest FDA decision is 2028, assuming Phase 3 confirms the Phase 2 findings

Natrlich

The right plan depends on your health history, tolerance, goals, and provider evaluation